FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS

YILMAZ, Eylül B.; Akçay, Şule; ulubay, gaye; S.BOZBAŞ, Şerife; akinci ozyurek, berna; EYÜBOĞLU, Fusun E.

FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS

Berna Akıncı ÖZYÜREK, (Atatürk Göğüs Hastalıkları ve Göğüs Cerrahisi Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Şerife S.BOZBAŞ, (Başkent Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Eylül B. YILMAZ, (Başkent Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Gaye ULUBAY, (Başkent Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Şule AKÇAY, (Başkent Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Fusun E. EYÜBOĞLU (Başkent Üniversitesi, Tıp Fakültesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)

Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi

0 0

Yıl: 2019 Cilt: 20 Sayı: 2 Sayfa Aralığı: 83 - 90 Metin Dili: İngilizce İndeks Tarihi: 08-10-2020

FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS

Öz:

OBJECTIVE: Recurrent bronchial infections lead to adecrease in pulmonary function and an increase inmortality and morbidity in patients with bronchiectasis.We aimed to evaluate mortality rate and identify riskfactors in mortality in patients with bronchiectasis.MATERIAL AND METHODS: In this study the records of104 patients who underwent high resolution computedtomography (HRCT) were evaluated. Demographicvariables, symptoms, physical examination findings,HRCT and pulmonary function test (PFT), culture andsputum analysis results, antibiotic resistance, infectionmarkers, need to stay in intensive care unit and mortalityrates were examined.RESULTS: The mean age was 59.5±15.1 years. Sputumproduction was detected in 65.4% of the cases andin 27.9% a microorganism was identified on sputumculture. Antibiotic resistance was detected in 11.5% ofthe cases. Infection episode, antibiotic resistance, age,smoking and respiratory insuffciency were associatedwith mortality (p<0.05 for all). A significant diffrencewas noted in FEV1% between patients with and withoutantibiotic resistance (p<0.05). There was negativeassociation between FEV1 and antibiotic resistance(r=-0.257, p=0.02), respiratory insuffciency (r=-0.288,p=0.01) and infection episodes (r=-0.329, p=0.003).Number of infection episode was higher in patients witha FEV1 <60% (p=0.003). Pulmonary hypertension wasdetected in 21.2% of the patients which was significantlymore common in tubular and bilateral bronchiectasis.CONCLUSIONS: Older age, smoking, infection episode,respiratory insuffciency and antibiotic resistance wereassociated with an increased risk of mortality. Ourfindings indicate that antibiotic resistance should bedetermined in patients with bronchiectasis who have aFEV1 value <60% as these cases have increased mortality.

Anahtar Kelime:

BRONŞEKTAZİLİ HASTALARDA MORTALİTE VE MORBİDİTEYİ ETKİLEYEN FAKTÖRLER

Öz:

AMAÇ: Bronşektazide tekrarlayan bronş enfeksiyonları; akciğer fonksiyonlarında azalma, mortalite ve morbiditede artışa yol açar. Çalışmamızda bronşektazide mortalite oranlarını ve mortaliteye yol açan risk faktörlerini değerlendirmeyi amaçladık. GEREÇ VE YÖNTEM: Çalışmaya yüksek rezolüsyonlu bilgisayarlı tomografisi (YRBT) olan 104 hasta dahil edildi. Demografik özellikleri, semptomları, fizik muayene bulguları, YRBT bulguları, solunum fonksiyon testleri, balgam analizleri ve kültür sonuçları, antibiyotik direnç- leri, infeksiyon parametreleri, yoğun bakım ihtiyaçları ve mortalite oranları retrospektif olarak değerlendirildi. BULGULAR: Ortalama yaş 59.5±15.1 idi. Hastaların % 65.4’ünün balgam şikayeti vardı, % 27.9’unda balgam kültüründe mikroorganizma saptandı. % 11.5 olguda antibiyotik direnci saptandı. Enfeksiyon sıklığı, antibiyotik direnci; yaş, sigara ve solunum yetmezliği mortalite ile ilişkili bulundu (p<0.05). Antibiyotik direnci olan ve olmayan hastalar arasında FEV1%’de farklılık saptandı (p<0.05). FEV1 ile antibiyotik direnci (r=-0.257, p=0.02), solunum yetmezliği (r=-0.288, p=0.01) ve infeksiyon sıklığı (r=- 0.329, p=0.003) arasında negatif ilişki saptandı. Sık enfeksiyon geçirenlerde FEV1 < % 60 olarak ölçüldü (p=0.003). Pulmoner hipertansiyon daha yaygın olarak tübüler ve bilateral bronşektazisi olan hastalarda bulundu (% 21.2). SONUÇ: Bronşektazide ileri yaş, sigara içimi, enfeksiyon sıklığı, solunum yetmezliği ve antibiyotik direnci mortalite riskinin artması ile ilişkilidir. Çalışmamızda antibiyotik direnci saptanan hastalarda FEV1 < % 60 olarak bulunmasının mortaliteyi artırdığını saptadık

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Martínez-García MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest. 2007;132:1565- 1572.
2. McGuinness G, Naidich DP, Leitman BS, McCauley DI. Bronchiectasis: CT evaluation. AJR Am J Roentgenol. 1993;160:253-259.
3. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors inflencing survival. Eur Respir J. 2009;34:843-849.
4. Naidich DP, McCauley DI, Khouri NF, Stitik FP, Siegelman SS. Computed tomography of bronchiectasis. J Comput Assist Tomogr. 1982;6: 437-444.
5. Miller MR, Crapo R, Hankinson J, et al. ATS/ERS Task Force. General considerations for lung function testing. Eur Respir J. 2005;26:153-161.
6. Berger M, Haimowitz A, Van Tosh A, Berdof RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol. 1985;6:359-365.
7. Barker AF. Bronchiectasis. N Engl J Med. 2002;246:1383– 1393.
8. Wong-You-Cheong JJ, Leahy BC, Taylor PM, Church SE. Airways obstruction and bronchiectasis: Correlation with duration of symptoms and extent of bronchiectasis on computed tomography. Clinical Radiology. 1992;45:256- 259.
9. Loubeyre P, Paret M, Revel D, Wiesendanger T, Brune J. Thin section CT detection of emphysema associated with bronchiectasis and correlation with pulmonary function test. Chest. 1996;109;2:360-365.
10. Grenier P, Mourey-Gerosa I, Benali K, et al. Abnormalities of the airways and lung parenchyma in asthmatics: CT observations in 50 patients and inter- and intra-observer variability. Eur Radiol. 1996;6:199–206.
11. Martinez-Garcia MA, Perpin˜a´ -Tordera M, Roma´n-Sanchez P, Soler-Catalun˜a JJ. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Resp Med. 2006;100:1623–1632.
12. Tsang KW, Ho PL, Lam WK, et al. Inhaled flticasone reduces sputum inflmmatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158:723-727.
13. Tsang KW, Tan KC, Ho PL, et al. Inhaled flticasone in bronchiectasis: a 12 month study. Thorax. 2005;60:239- 243.
14. Angrill J, Agustí C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57:15-19.
15. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187:1118-1126.
16. Guan WJ, Gao YH, Xu G, et al. Sputum bacteriology in steady-state bronchiectasis in Guangzhou, China. Int J Tuberc Lung Dis. 2015 May;19(5):610-9. doi: 10.5588/ ijtld.14.0613.
17. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med. 2007;101:1633-1638.
18. Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the inflence of Pseudomonas aeruginosa. Eur Respir J. 1996;9:1601- 1604.
19. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ ERS position paper. ATS/ERS Task Force. Eur Respir J. 2004;23:932-946.
20. Peinado VI, Barberá JA, Abate P, et al. Inflmmatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;159:1605-1611.
21. Yonghua Chen, Chunli Liu, Wenju Lu, et al. Clinical characteristics and risk factors of pulmonary hypertension associated with chronic respiratory diseases: a retrospective study. J Thorac Dis. 2016 Mar; 8(3): 350–358. doi: 10.21037/jtd.2016.02.58
22. Alzeer AH, Al-Mobeirek AF, Al-Otair HA, et al. Right and left ventricular function and pulmonary artery pressure in patients with bronchiectasis.Chest. 2008;133:468- 473.
23. Keistinen T, Säynäjäkangas O, Tuuponen T, Kivelä SL. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J. 1997;10:2784-2787.
24. Finklea JD, Khan G, Thomas S, Song J, Myers D, Arroliga AC. Predictors of mortality in hospitalized patients with acute exacerbation of bronchiectasis. Respir Med. 2010;104:816-821.
25. Chalmers JD, Goeminne P, Aliberti S, et al. The Bronchiectasis Severity İndex: An İnternational Derivation And Validation Study. Am J Respir Crit Care Med 2014; 189: 576-585.
26. Wilson CB, Jones PW, O’Leary CJ, et al. Systemic markers of inflmmation in stable bronchiectasis. Eur Respir J. 1998;12:820–824.
27. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest. 1995;107:1342–1349.

APA	akinci ozyurek b, S.BOZBAŞ Ş, YILMAZ E, ulubay g, Akçay Ş, EYÜBOĞLU F (2019). FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS. , 83 - 90.
Chicago	akinci ozyurek berna,S.BOZBAŞ Şerife,YILMAZ Eylül B.,ulubay gaye,Akçay Şule,EYÜBOĞLU Fusun E. FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS. (2019): 83 - 90.
MLA	akinci ozyurek berna,S.BOZBAŞ Şerife,YILMAZ Eylül B.,ulubay gaye,Akçay Şule,EYÜBOĞLU Fusun E. FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS. , 2019, ss.83 - 90.
AMA	akinci ozyurek b,S.BOZBAŞ Ş,YILMAZ E,ulubay g,Akçay Ş,EYÜBOĞLU F FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS. . 2019; 83 - 90.
Vancouver	akinci ozyurek b,S.BOZBAŞ Ş,YILMAZ E,ulubay g,Akçay Ş,EYÜBOĞLU F FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS. . 2019; 83 - 90.
IEEE	akinci ozyurek b,S.BOZBAŞ Ş,YILMAZ E,ulubay g,Akçay Ş,EYÜBOĞLU F "FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS." , ss.83 - 90, 2019.
ISNAD	akinci ozyurek, berna vd. "FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS". (2019), 83-90.

APA	akinci ozyurek b, S.BOZBAŞ Ş, YILMAZ E, ulubay g, Akçay Ş, EYÜBOĞLU F (2019). FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi, 20(2), 83 - 90.
Chicago	akinci ozyurek berna,S.BOZBAŞ Şerife,YILMAZ Eylül B.,ulubay gaye,Akçay Şule,EYÜBOĞLU Fusun E. FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi 20, no.2 (2019): 83 - 90.
MLA	akinci ozyurek berna,S.BOZBAŞ Şerife,YILMAZ Eylül B.,ulubay gaye,Akçay Şule,EYÜBOĞLU Fusun E. FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi, vol.20, no.2, 2019, ss.83 - 90.
AMA	akinci ozyurek b,S.BOZBAŞ Ş,YILMAZ E,ulubay g,Akçay Ş,EYÜBOĞLU F FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi. 2019; 20(2): 83 - 90.
Vancouver	akinci ozyurek b,S.BOZBAŞ Ş,YILMAZ E,ulubay g,Akçay Ş,EYÜBOĞLU F FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS. Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi. 2019; 20(2): 83 - 90.
IEEE	akinci ozyurek b,S.BOZBAŞ Ş,YILMAZ E,ulubay g,Akçay Ş,EYÜBOĞLU F "FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS." Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi, 20, ss.83 - 90, 2019.
ISNAD	akinci ozyurek, berna vd. "FACTORS AFFECTING MORTALITY AND MORBIDITY IN PATIENTS WITH BRONCHIECTASIS". Afyon Kocatepe Üniversitesi Kocatepe Tıp Dergisi 20/2 (2019), 83-90.